
1. Participant Flow



2. <u>Baseline Characteristics</u>

Baseline Characteristics	Gi	Groups		
Demographic data:	Control group	Experimental group		
Age (mean \pm SD)	33.6 ± 6.3	33.2 ± 6		
Sex; count (%)				
Males	12 (30%)	18 (45%)		
Females	28 (70%)	22 (55%)		
Ethnicity	Asian	Asian		
Pre-operative pain score (mean ± SD)	13.1 ± 17.4	18.1 ± 12.4		
<i>Teeth included in the study; count (%)</i>	15.1 ± 17.4	10.1 ± 12.4		
Maxillary Central Incisor	4 (10%)	2 (5%)		
Maxillary Lateral Incisor	4 (10%)	4 (10%)		
Maxillary Canine	8 (20%)	7 (17.5%)		
Maxillary 2 nd Premolar	6 (15%)	14 (35%)		
Mandibular Central Incisor				
Mandibular Lateral Incisor	3 (7.5%)			
Mandibular Canine	1 (2.5%)	2 (5%)		
Mandibular 1 st Premolar	4 (10%)	5 (12.5%)		
Mandibular 2 nd Premolar	10 (25%)	6 (15%)		

3. <u>OUTCOME MEASURES</u>

PRIMARY OUTCOME (1a):

Difference of mean pain scores between the groups; without exclusion of patients who took analgesics

Interval	<u>N</u> (33)	<u>Group I Mean Pain</u> <u>Score</u> (min – max)	<u>N</u> (35)	<u>Group II Mean Pain</u> <u>Score</u> (min – max)	<u>Mean</u> <u>Difference (P-</u> <u>value)</u>
Pre-op		14.7 ± 18.3 (1 - 90)		20.6 ± 17.3 (2 - 50)	-5.87 (0.053*)
4 hours		11.8 ± 18.7 (0 - 70)		8.8 ± 11.1 (0 - 43)	2.96 (0.329)
12 hours		9.4 ± 16.7 (0 - 50)		10.3 ± 13.3 (0 - 49)	-0.92 (0.764)
Day 2		3.5 ± 7.7 (0 - 30)		5.1 ± 9.2 (0 - 30)	-1.57 (0.605)
Day 3		2.6 ± 6.4 (0 - 30)		3.4 ± 6.8 (0 - 25)	-0.82 (0.786)
Day 4		1.9 ± 4.7 (0 - 20)		2.7 ± 7.3 (0 - 30)	-0.72 (0.813)

* Significant at 0.05

PRIMARY OUTCOME (1b):

Difference of mean pain scores between the groups; with exclusion of patients who took analgesics

Interval	<u>N</u>	<u>Group I Mean Pain</u> <u>Score</u> (min – max)	<u>N</u>	<u>Group II Mean Pain</u> <u>Score</u> (min – max)	<u>Mean</u> <u>Difference (P-</u> <u>value)</u>
4 hours	26	3.1 ± 5.3 (0 - 23)	32	6.6 ± 8.3 (0 - 24)	-3.49 (0.146)
12 hours	26	1.4 ± 3.6 (0 - 15)	26	4.3 ± 6.6 (0 - 20)	-2.92 (0.245)
Day 2	26	0.5 ± 1.4 (0 - 5)	25	1.4 ± 3.0 (0 - 10)	-0.94 (0.712)
Day 3	26	0.8 ± 2.2 (0 - 9)	25	1.4 ± 3.5 (0 - 12)	-0.63 (0.803)
Day 4	26	0.6 ± 1.2 (0 - 9)	24	0.5 ± 2.0 (0 - 10)	0.08 (0.976)

SECONDARY OUTCOME (1):

Incidence of flare-up

Time Interval	Caoh (%)	Propolis (%)	Total (%)
	N= 33	N= 35	
4 hours	4 (5.9%)	1 (1.5%)	5 (7.4%)
12 hours	0 (0%)	4 (5.9%)	4 (5.9%)
Day 2	0 (0%)	1 (1.5%)	1 (1.5%)
Day 3	0 (0%)	0 (0%)	0 (0%)
Day 4	0 (0%)	0 (0%)	0 (0%)
Total (%)	4 (5.9%)	6 (8.9%)	10 (14.8%)

SECONDARY OUTCOME (2a):

Comparison of pain scores between the various time intervals; without exclusion of patients who
took analgesics

Time	Pre-op	4 hours	12 hours	Day 2	Day 3	Day 4
Pre-op	C →	2.97 (0.334)	5.30 (0.085)	11.18 (0.000**)	12.12 (0.000**)	12.79 (0.000**)
4 hours	11.80 (0.000**)	C → ← E	2.33 (0.448)	8.21 (0.008**)	9.15 (0.003**)	9.82 (0.001**)
12 hours	10.26 (0.001**)	-1.54 (0.605)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	5.88 (0.056*)	6.82 (0.27)	7.84 (0.015**)
Day 2	15.49 (0.000**)	3.69 (0.217)	5.23 (0.80)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	0.94 (0.760)	1.61 (0.601)
Day 3	17.17 (0.000**)	5.37 (0.72)	6.91 (0.21)	1.69 (0.574)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	0.67 (0.828)
Day 4	17.94 (0.000**)	6.14 (0.40)	7.69 (0.10)	2.46 (0.410)	0.77 (0.796)	← E

** significant at 0.01, * significant at 0.05

 $C \rightarrow$ = control group values, $\leftarrow E$ = Experimental group values

SECONDARY OUTCOME (2b):

Comparison of pain scores between the various time intervals; with exclusion of patients who
took analgesics

Time	Pre-op	4 hours	12 hours	Day 2	Day 3	Day 4
Pre-op	$C \rightarrow$	11.65 (0.000**)	13.34 (0.000**)	14.27 (0.000**)	13.92 (0.000**)	14.15 (0.000**)
4 hours	14.04	(0.000)	1.69	2.62	2.27	2.5
+ nours	(0.000**)	← E	(0.501)	(0.298)	(0.367)	(0.320)
12 hours	16.29 (0.000**)	2.25 (0.346)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	0.92 (0.713)	0.58 (0.818)	0.81 (0.748)
Day 2	19.20 (0.000**)	5.16 (0.33)	2.91 (0.252)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	-0.35 (0.890)	-0.12 (0.963)
Day 3	19.16 (0.000**)	5.12 (0.035*)	2.87 (0.259)	-0.4 (0.988)	$\begin{array}{c} C \rightarrow \\ \leftarrow E \end{array}$	0.23 (0.927)
Day 4	20.10 (0.000**)	6.06 (0.014**)	0.381 (0.138)	0.90 (0.728)	0.94 (0.717)	← E

** significant difference at 0.01, * significant at 0.05

 $C \rightarrow$ = Control group values, $\leftarrow E$ = Experimental group values

OTHER OUTCOME (1a):

Interva <u>l</u>	<u>N</u>	<u>Males Mean Pain</u> <u>Score</u> (min – max)	<u>N</u>	<u>Females Mean</u> <u>Pain Score</u> <u>(min – max)</u>	<u>Mean</u> Difference (P- <u>value)</u>
4 hours	25	9.8 ± 11.9 (0 - 40)	43	10.4 ± 16.9 (0 - 70)	-0.6 (0.412)
12 hours	25	11.6 ± 14.5 (0 - 49)	43	8.8 ± 15.2 (0 - 50)	2.8 (0.94)
Day 2	25	7.8 ± 11 (0 - 30)	43	2.3 ± 5.8 (0 - 25)	5.5 (0.035*)
Day 3	25	5.8 ± 8.9 (0 - 30)	43	1.40 ± 4 (0 - 20)	4.4 (0.023*)
Day 4	25	5 ± 9.2 (0 - 30)	43	0.70 ± 2.1 (0 - 9)	4.3 (0.020*)

Quantitative analysis of pain score among genders

* Significant at 0.05

OTHER OUTCOME (1b):

Time	Gender	No or mild	Moderate	Severe pain	Total
Interval		pain (%)	pain (%)	(%)	
4 hours	Male	21 (30.9%)	4 (5.9%)	0	68
	Female	37 (54.4%)	3 (4.4%)	3 (4.4%)	
12 hours	Male	19 (27.9%)	6 (8.8%)	0	68
	Female	36 (52.9%	5 (7.4%)	2 (2.9%)	
Day 2	Male	21 (30.9%)	4 (5.9%)	0	68
	Female	41 (60.3%)	2 (2.9%)	0	
Day 3	Male	23 (33.8%)	2 (2.9%)	0	68
	Female	43 (63.2%)	0	0	
Day 4	Male	23 (33.8%)	2 (2.9%)	0	68
	Female	43 (63.2%)	0	0	

The qualitative analysis of pain among genders

OTHER OUTCOME (2a):

Time Interval	20 - 24	25- 29 (N=	30 - 34	35 – 40	P - value
	(N=6)	10)	(N=17)	(N=35)	
		MEAN	RANK		
4 hours	32.9	44.7	37.5	30.3	<u>0.15</u>
12 hours	30.8	36.5	40.6	31.5	<u>0.36</u>
Day 2	24	43.1	35.3	33.4	<u>0.13</u>
Day 3	30.7	33.2	31.3	37	<u>0.55</u>
Day 4	27	33.7	30.5	37.9	<u>0.17</u>

The difference of pain scores between the age groups

OTHER OUTCOME (2b):

The types of pain prevalent among age groups

Time	Pain severity	20 to 24 (%)	25 to 29 (%)	30 to 34 (%)	35 to 40 (%)
4 hours	No or mild	6 (9%)	8 (12%)	13 (19%)	31 (46%)
	Mod	0	2 (3%)	2 (3%)	3 (4%)
	Severe	0	0	2 (3%)	1 (1.5%)
10	N7 11	<i>E</i> (70())	7 (100/)	12 (100/)	20 (140()
12	No or mild	5 (7%)	7 (10%)	13 (19%)	30 (44%)
hours	Moderate	1 (1.5%)	3 (4%)	3 (4%)	4 (6%)
-	Severe	0	0	1 (1.5%)	1 (1.5%)
Day 2	No or mild	6 (9%)	7 (10%)	16 (23.5%)	33 (48.5%)
	Moderate	0	3 (4%)	1 (1.5%)	2 (3%)
-	Severe	0	0	0	0
Day 3	No or mild	6 (9%)	9 (13%)	17 (25%)	34 (50%)
	Moderate	0	1 (1.5%)	0	1 (1.5%)
-	Severe	0	0	0	0
Day 4	No or mild	6 (9%)	10 (15%)	17 (25%)	33 (48.5%)
<i>-</i>	Moderate	0	0	0	2 (3%)
-	severe	0	0	0	0

OTHER OUTCOME (3):

Type of analgesics required by patients during study

Groups	Time	No	ОТС	Narcotic
	Interval	medication	medication	medication
Control Group (Calcium hydroxide/Calcipulpe)	4 hrs	26 (38%)	4 (6%)	3 (4%)
Experimental Group (Propolis)		32 (47%)	3 (4%)	0
Total		58 (85%)	7 (10%)	3 (4%)
Control Group (Calcium hydroxide/Calcipulpe)	12 hrs	27 (40%)	4 (6%)	2 (3%)
Experimental Group (Propolis)		28 (41%)	7 (10%)	0
Total		55 (81%)	11 (16%)	2 (3%)
Control Group (Calcium hydroxide/Calcipulpe)	Day 2	31 (46%)	2 (3%)	0
Experimental Group (Propolis)		31 (46%)	4 (6%)	0
Total		62 (91%)	6 (9%)	0
Control Group (Calcium hydroxide/Calcipulpe)	Day 3	32 (47%)	1 (1.5%)	0
Experimental Group (Propolis)		34 (50%)	1 (1.5%)	0
Total		66 (97%)	2 (3%)	0
Control Group (Calcium hydroxide/Calcipulpe)	Day 4	33 (48.5%)	0	0
Experimental Group (Propolis)		33 (48.5%)	2 (3%)	0
Total		66 (97%)	2 (3%)	0

4. Adverse Events

There were no adverse events associated with this trial.